1-(5-Cyclopropyl-3-methylpyridin-2-yl)piperazine → N-(1-{4-[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-1-methylethyl)methanesulfonamide
반응식
[CH3:1][S:2]([NH:5][C:6]([C:9]1[CH:18]=[CH:17][C:12]([C:13]([O:15]C)=O)=[CH:11][CH:10]=1)([CH3:8])[CH3:7])(=[O:4])=[O:3].[CH:19]1([C:22]2[CH:23]=[C:24]([CH3:34])[C:25]([N:28]3[CH2:33][CH2:32][NH:31][CH2:30][CH2:29]3)=[N:26][CH:27]=2)[CH2:21][CH2:20]1>>[CH:19]1([C:22]2[CH:23]=[C:24]([CH3:34])[C:25]([N:28]3[CH2:29][CH2:30][N:31]([C:13]([C:12]4[CH:11]=[CH:10][C:9]([C:6]([NH:5][S:2]([CH3:1])(=[O:3])=[O:4])([CH3:7])[CH3:8])=[CH:18][CH:17]=4)=[O:15])[CH2:32][CH2:33]3)=[N:26][CH:27]=2)[CH2:21][CH2:20]1참가 물질
3
실험 절차
Using methyl 4-(1-methanesulfonylamino-1-methylethyl)benzoate (126 mg) described in Preparation Example 71 and 1-(5-cyclopropyl-3-methylpyridin-2-yl)piperazine (101 mg) described in Preparation Example 83 and by the reaction and treatment in the same manner as in Example 109, the title compound (162 mg) was obtained.
후처리
- custom